Ovid Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.5
- Today's High:
- $3.665
- Open Price:
- $3.5
- 52W Low:
- $1.405
- 52W High:
- $4.139
- Prev. Close:
- $3.5
- Volume:
- 66351
Company Statistics
- Market Cap.:
- $247.11 million
- Book Value:
- 1.568
- Revenue TTM:
- $198542
- Operating Margin TTM:
- -27420.42%
- Gross Profit TTM:
- $1.50 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.7%
- Return on Equity TTM:
- -37.47%
Company Profile
Ovid Therapeutics Inc had its IPO on 2017-05-05 under the ticker symbol OVID.
The company operates in the Healthcare sector and Biotechnology industry. Ovid Therapeutics Inc has a staff strength of 40 employees.
Stock update
Shares of Ovid Therapeutics Inc opened at $3.5 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.5 - $3.67, and closed at $3.65.
This is a +4.29% increase from the previous day's closing price.
A total volume of 66,351 shares were traded at the close of the day’s session.
In the last one week, shares of Ovid Therapeutics Inc have increased by +3.11%.
Ovid Therapeutics Inc's Key Ratios
Ovid Therapeutics Inc has a market cap of $247.11 million, indicating a price to book ratio of 0.9028 and a price to sales ratio of 87.0877.
In the last 12-months Ovid Therapeutics Inc’s revenue was $198542 with a gross profit of $1.50 million and an EBITDA of $-53818532. The EBITDA ratio measures Ovid Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ovid Therapeutics Inc’s operating margin was -27420.42% while its return on assets stood at -21.7% with a return of equity of -37.47%.
In Q2, Ovid Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.4%.
Ovid Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 1.7918
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 1.7918 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ovid Therapeutics Inc’s profitability.
Ovid Therapeutics Inc stock is trading at a EV to sales ratio of 4.5596 and a EV to EBITDA ratio of -0.0966. Its price to sales ratio in the trailing 12-months stood at 87.0877.
Ovid Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $136.23 million
- Total Liabilities
- $10.14 million
- Operating Cash Flow
- $20.07 million
- Capital Expenditure
- $117434
- Dividend Payout Ratio
- 0%
Ovid Therapeutics Inc ended 2024 with $136.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $136.23 million while shareholder equity stood at $110.70 million.
Ovid Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.14 million in other current liabilities, 70603.00 in common stock, $-251291081.00 in retained earnings and $0 in goodwill. Its cash balance stood at $71.62 million and cash and short-term investments were $96.52 million. The company’s total short-term debt was $944,943 while long-term debt stood at $0.
Ovid Therapeutics Inc’s total current assets stands at $102.17 million while long-term investments were $16.47 million and short-term investments were $24.89 million. Its net receivables were $0 compared to accounts payable of $3.76 million and inventory worth $0.
In 2024, Ovid Therapeutics Inc's operating cash flow was $20.07 million while its capital expenditure stood at $117434.
Comparatively, Ovid Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.65
- 52-Week High
- $4.139
- 52-Week Low
- $1.405
- Analyst Target Price
- $5.67
Ovid Therapeutics Inc stock is currently trading at $3.65 per share. It touched a 52-week high of $4.139 and a 52-week low of $4.139. Analysts tracking the stock have a 12-month average target price of $5.67.
Its 50-day moving average was $3.54 and 200-day moving average was $2.9 The short ratio stood at 13.33 indicating a short percent outstanding of 0%.
Around 2082.6% of the company’s stock are held by insiders while 5582.6% are held by institutions.
Frequently Asked Questions About Ovid Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.